<DOC>
	<DOC>NCT00032773</DOC>
	<brief_summary>To determine a safe and effective dose of pentostatin in steroid-refractory aGvHD and to identify the minimal effective dose of pentostatin defined as the lowest dose that produces a response in 20% or more of patients while producing treatment failure (defines as death, grade 3/4 toxicity, or progressive disease) in 40% or less of patients.</brief_summary>
	<brief_title>Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD</brief_title>
	<detailed_description />
	<mesh_term>Graft vs Host Disease</mesh_term>
	<mesh_term>Pentostatin</mesh_term>
	<criteria>Inclusion: Patients 6 months of age with grade 2 GVHD that is steroidrefractory Must be engrafted with ANC 1000/mL, may still be transfusion dependent for platelets and PRBC Time post stem cell infusion &lt; 100 days Written informed consent Must have adequate renal function (creatinine clearance 40 mL/min/1.73 m2 Exclusion: Posttransplant lymphoproliferative disease Uncontrolled infection Mental illness or other condition preventing full cooperation with the treatment and monitoring requirements of the study ATG within the previous 14 days Other immunosuppressive agents (including monoclonal antibodies) when initiated within the previous 7 days.</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2005</verification_date>
	<keyword>acute graft versus host disease</keyword>
	<keyword>aGVHD</keyword>
	<keyword>allogeneic hematopoietic stem cell transplantation</keyword>
	<keyword>peripheral blood stem cell transplantation</keyword>
	<keyword>cord blood transplant</keyword>
	<keyword>pentostatin</keyword>
	<keyword>Nipent</keyword>
	<keyword>deoxycoformycin</keyword>
</DOC>